Fig. 5.

Effects of fluvastatin on the phosphorylations of ERK1/2, p38 MAPK, Akt, and Bad. After treatment with fluvastatin, phospho-Akt expression was suppressed whereas phosphorylations of ERK1/2 and p38 MAPK were sustained. Furthermore, phospho-Bad expression was significantly reduced. (A) TNFα-stimulated SW982 cells were treated with fluvastatin for 24 h. Cell lysates were subjected to SDS-PAGE and immunoblotted with anti-phospho-ERK1/2, anti-phospho-p38 MAPK, anti-phospho-Akt, or anti-phospho-Bad antibodies. Equal amounts of protein were loaded in each lane, and equal loading was confirmed by immunoblotting with an anti-β-actin antibody. (B) TNFα-stimulated SW982 cells were incubated for 24 h in the presence of 10 μM fluvastatin, 50 μM PD98059, 10 μM SB203580, or 15 μM LY294002. Apoptosis was measured by flow cytometry after staining with annexin V. The results are representative of two independents experiments. *P<0.05 compared to control (medium only).